adagio

  • Home
  • About us
  • Cancer Vaccine Program
  • Multiple Myeloma
Innovative immuno-therapeutics for Cancer Learn More

welcome

OncoPep is developing targeted immunotherapeutics to prevent the progression of cancer, prolong survival and restore the quality of life of patients. OncoPep's lead program is a therapeutic cancer vaccine for use in treating smoldering multiple myeloma.

Learn More

news

OncoPep Announces Initiation of Phase 1b Clinical Trial of PVX-410 in Smoldering Multiple Myeloma and Upcoming Presentation of Positive Results from Phase 1/2a Clinical Trial at ASH 11-28-2016

OncoPep Announces Initiation of Phase 1b Clinical Trial of PVX-410 in Triple Negative Breast Cancer 11-28-2016

OncoPep Presents Updated Results of a Phase 1/2a Clinical Trial with Multi-Peptide Vaccine to Treat Smoldering Multiple Myeloma 12-07-2015

OncoPep Raises $6.9 Million Series B Financing to Advance Novel Cancer Vaccines and Expands Phase 1/2a Clinical Trial 08-28-2014

OncoPep Initiates Phase 1/2a Clinical Trial with Multi-Peptide Vaccine to Treat Smoldering Multiple Myeloma 01-29-2013

OncoPep Announces Publication in Clinical Cancer Research 07-16-2012

OncoPep Announces Publication in The British Journal of Haematology 07-16-2012

  • Home      |
  • Site Map      |
  • Contact Us

OncoPep © 2014  |  Privacy Policy